Table 2.
Multivariate analysis of prognostic factors in 491 nasopharyngeal carcinoma patients receiving IMRT
| Endpoint | Variable | HR | HR (95 % CI) | P value |
|---|---|---|---|---|
| OS | N Stage(0) | Ref | Ref | 0.001 |
| N Stage(1) | 1.172 | 0.252- 5.453 | 0.839 | |
| N Stage(2) | 1.767 | 0.393- 7.950 | 0.458 | |
| N Stage(3) | 7.404 | 1.494- 36.684 | 0.014 | |
| Low-dose group | Ref | Ref | 0.001 | |
| Median-dose group | 0.135 | 0.045-0.405 | <0.001 | |
| High-dose group | 0.225 | 0.069-0.734 | 0.013 | |
| EBV DNA | 4.953 | 2.200-11.153 | <0.001 | |
| DMFS | EBV DNA | 3.669 | 2.058-6.540 | <0.001 |
HR hazard ratio, CI confidence interval, Ref reference, OS overall survival, DMFS distant metastasis free survival, EBV DNA Epstein–Barr virus deoxyribonucleic acid. P value < 0.05 is statistically significant